Jaguar Health, Inc. (JAGX): Price and Financial Metrics
GET POWR RATINGS... FREE!
JAGX POWR Grades
- Sentiment is the dimension where JAGX ranks best; there it ranks ahead of 81.77% of US stocks.
- JAGX's strongest trending metric is Value; it's been moving down over the last 179 days.
- JAGX ranks lowest in Stability; there it ranks in the 0th percentile.
JAGX Stock Summary
- Revenue growth over the past 12 months for Jaguar Health Inc comes in at -53.81%, a number that bests only 2.91% of the US stocks we're tracking.
- The volatility of Jaguar Health Inc's share price is greater than that of 95.49% US stocks with at least 200 days of trading history.
- Jaguar Health Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -105.28%, greater than the shareholder yield of only 3.61% of stocks in our set.
- If you're looking for stocks that are quantitatively similar to Jaguar Health Inc, a group of peers worth examining would be ESPR, LMNL, EYPT, QMCO, and PROG.
- JAGX's SEC filings can be seen here. And to visit Jaguar Health Inc's official web site, go to www.jaguar.health.
JAGX Valuation Summary
- JAGX's price/earnings ratio is -3.7; this is 110.14% lower than that of the median Healthcare stock.
- Over the past 77 months, JAGX's price/sales ratio has gone NA NA.
- Over the past 77 months, JAGX's price/sales ratio has gone NA NA.
Below are key valuation metrics over time for JAGX.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| JAGX | 2021-08-31 | 24.0 | 5.3 | -3.7 | -4.4 |
| JAGX | 2021-08-30 | 24.0 | 5.3 | -3.7 | -4.4 |
| JAGX | 2021-08-27 | 24.4 | 5.4 | -3.7 | -4.5 |
| JAGX | 2021-08-26 | 24.2 | 5.3 | -3.7 | -4.4 |
| JAGX | 2021-08-25 | 24.4 | 5.4 | -3.7 | -4.5 |
| JAGX | 2021-08-24 | 24.0 | 5.3 | -3.7 | -4.4 |
JAGX Growth Metrics
- The 2 year net income to common stockholders growth rate now stands at -87.26%.
- The 5 year revenue growth rate now stands at 2058.76%.
- Its 3 year revenue growth rate is now at 2121.54%.
The table below shows JAGX's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2021-12-31 | 4.335 | -34.97 | -52.595 |
| 2021-09-30 | 4.832 | -30.108 | -49.646 |
| 2021-06-30 | 6.975 | -23.595 | -45.725 |
| 2021-03-31 | 9.757 | -17.69 | -42.241 |
| 2020-12-31 | 9.385 | -15.278 | -38.648 |
| 2020-09-30 | 8.316051 | -14.35629 | -35.3023 |
JAGX's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- JAGX has a Quality Grade of C, ranking ahead of 26.4% of graded US stocks.
- JAGX's asset turnover comes in at 0.128 -- ranking 241st of 682 Pharmaceutical Products stocks.
- VYGR, MDVL, and NERV are the stocks whose asset turnover ratios are most correlated with JAGX.
The table below shows JAGX's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.128 | 0.596 | -2.417 |
| 2021-03-31 | 0.211 | 0.673 | -4.961 |
| 2020-12-31 | 0.250 | 0.651 | 109.795 |
| 2020-09-30 | 0.232 | 0.611 | 7.457 |
| 2020-06-30 | 0.182 | 0.479 | 28.507 |
| 2020-03-31 | 0.143 | 0.282 | -249.492 |
JAGX Price Target
For more insight on analysts targets of JAGX, see our JAGX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $13.50 | Average Broker Recommendation | 1.25 (Strong Buy) |
JAGX Stock Price Chart Interactive Chart >
JAGX Price/Volume Stats
| Current price | $0.40 | 52-week high | $6.84 |
| Prev. close | $0.39 | 52-week low | $0.34 |
| Day low | $0.39 | Volume | 1,772,900 |
| Day high | $0.44 | Avg. volume | 3,327,658 |
| 50-day MA | $0.50 | Dividend yield | N/A |
| 200-day MA | $1.42 | Market Cap | 30.73M |
Jaguar Health, Inc. (JAGX) Company Bio
Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing gastrointestinal products for human prescription use and animals worldwide. It operates through two reportable segments, Human Health and Animal Health. The company, through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals. Its human health product pipelines include crofelemer, which is in Phase III clinical trial for the treatment of cancer therapy-related diarrhea, as well as for the supportive care for inflammatory bowel disease; formulation of crofelemer that is Phase II clinical trial for the treatment of short bowel syndrome, congenital diarrheal disorders, idiopathic/functional diarrhea, and irritable bowel; and SB-300, a second-generation anti-secretory agent for various indications, including cholera. The company's animal health product candidates comprise Canalevia, an animal prescription drug product candidate intended for treatment of chemotherapy-induced diarrhea in dogs; and Equilevia, a non-prescription product for total gut health in equine athletes. In addition, its products include Neonorm Calf and Neonorm Foal. Jaguar Health, Inc. was founded in 2013 and is headquartered in San Francisco, California.
Latest JAGX News From Around the Web
Below are the latest news stories about Jaguar Health Inc that investors may wish to consider to help them evaluate JAGX as an investment opportunity.
Is Jaguar Health Inc. (NASDAQ: JAGX) Still A Buy After A -18.10% Weekly Drop?During the last session, Jaguar Health Inc. (NASDAQ:JAGX)’s traded shares were 1.44 million, with the beta value of the company hitting 1.52. At the end of the trading day, the stock’s price was $0.60, reflecting an intraday loss of -4.88% or -$0.03. The 52-week high for the JAGX share is $10.02, that puts it down … Is Jaguar Health Inc. (NASDAQ: JAGX) Still A Buy After A -18.10% Weekly Drop? Read More » |
Jaguar Animal Health Seeks MUMS Designation from FDA for Canalevia (Crofelemer) for Treatment of Exercise-induced Diarrhea (EID) in DogsIn December of 2021, FDA conditionally approved Canalevia ™ -CA1 for treatment of chemotherapy-induced diarrhea in dogs, and the company expects Canalevia could receive FDA conditional approval, under the name Canalevia ™ -CA2, for treatment of EID in dogs SAN FRANCISCO, CA / ACCESSWIRE / February |
Jaguar Health Announces Receipt by Napo Therapeutics of Small and Medium Enterprise (SME) Designation from the European Medicines AgencySME status is an important designation for Italy-based Napo Therapeutics' rare/orphan disease business modelSAN FRANCISCO, CA and MILAN, ITALY / ACCESSWIRE / February 15, 2022 / Jaguar Health (NASDAQ:JAGX) and Napo Therapeutics S., an Italian corporation established by Jaguar Health in Milan, Italy, today announced that Napo Therapeutics has been granted Small and Medium Enterprise (SME) designation by the European Medicines Agency (EMA). |
Jaguar Health Completes Final Major Regulatory Filing for Conditional New Animal Drug Approval of Canalevia (Crofelemer) to Treat Exercise-induced Diarrhea in DogsCanalevia ™ would be first and only FDA-approved plant-based medicine for working dogs that suffer from diarrhea SAN FRANCISCO, CA / ACCESSWIRE / February 10, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX), under its Jaguar Animal Health tradename for the veterinary market, today announced that it has |
Jaguar Health files for conditional FDA approval of canine therapy CanaleviaJaguar Health < |
JAGX Price Returns
| 1-mo | -20.13% |
| 3-mo | -26.94% |
| 6-mo | -71.01% |
| 1-year | -89.97% |
| 3-year | -98.94% |
| 5-year | -99.98% |
| YTD | -61.54% |
| 2021 | -57.46% |
| 2020 | 1.75% |
| 2019 | -95.00% |
| 2018 | -89.10% |
| 2017 | -80.56% |
Continue Researching JAGX
Here are a few links from around the web to help you further your research on Jaguar Health Inc's stock as an investment opportunity:Jaguar Health Inc (JAGX) Stock Price | Nasdaq
Jaguar Health Inc (JAGX) Stock Quote, History and News - Yahoo Finance
Jaguar Health Inc (JAGX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...